China Type II Inflammatory Skin Disease Clinical Research and Standardized Diagnosis and Treatment Project
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorPeking University First Hospital
About this trial
In order to further improve the diagnosis and treatment level of type 2 inflammatory skin diseases, the National Clinical Center for Skin and Immune Diseases established a standardized diagnosis and treatment center for type 2 inflammatory skin diseases to systematically and effectively understand the current treatment status of patients with type 2 inflammatory skin diseases, as well as the efficacy and safety of various treatment methods during practices, so as to further improve the diagnosis and treatment level of type 2 inflammatory skin diseases and help patients with type 2 inflammatory skin diseases.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients from the medical units that has passed the data review of the National Clinical Center for Skin and Immune Diseases (see the study sites for data collection for details);
patients diagnosed with type 2 inflammatory skin diseases (dermatitis/eczema, urticaria, pemphigoid, prurigo nodularis).
Disqualifiers
patients who fail to provide informed consent form;
patients who cannot complete the questionnaire independently or under the guidance of investigators
Trial population
Patients with Type 2 skin disease. Estimated number of patients: 100,000 (No age limit)
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Demographics
Age, sex, ethnicity, body weight and height
Time frame
baseline2
Age at Type 2 skin disease onset
Age of study patients at time of Type 2 skin disease onset
Time frame
baseline3
Type of current Type 2 skin disease therapy
Type of therapy administered to treat Type 2 skin disease (e.g., systemic, topical, other)
Time frame
Baseline4
Presence of Type 2 skin disease and selected comorbid conditions
Percentage of patients with Type 2 skin disease and selected comorbidities (e.g., asthma and allergic rhinitis) at baseline and during study
Time frame
Baseline to Month 120Secondary outcomes
1
Percentage of patients using specific Type 2 skin disease therapies and initiating new therapies
Percentage of patients using specific Type 2 skin disease therapies and initiating new therapies
Time frame
Baseline to Month 1202
Eczema Area and Severity Index (EASI)
EASI score as assessed by physician
Time frame
Baseline to Month 1203
Body Surface Area (BSA) percentage affected by Type 2 skin disease
BSA score as assessed by physician
Time frame
Baseline to Month 1204
Patient Oriented Eczema Measure (POEM) questionnaire
POEM score as reported by the participant's caregiver
Time frame
Baseline to Month 120Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov